Cytokinetics(US:CYTK) Globenewswireยท2025-10-06 03:34Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated due to misleading statements regarding the New Drug Application (NDA) for aficamten, which may have led to investor losses [4][6][8]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Cytokinetics between December 27, 2023, and May 6, 2025, to discuss their legal rights [1][4]. - There is a deadline of November 17, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [4]. Group 2: Misleading Statements - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission timeline and approval process for aficamten, specifically regarding the expected FDA approval in the second half of 2025 [6]. - It was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy (REMS), which misled investors about the regulatory timeline [7]. Group 3: Investor Impact - As a result of the misleading statements, investors purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was disclosed [8]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, overseeing the litigation on behalf of the class [9].